Fatty liver--an additional and treatable feature of the insulin resistance syndrome - PubMed (original) (raw)
Fatty liver--an additional and treatable feature of the insulin resistance syndrome
H Knobler et al. QJM. 1999 Feb.
Abstract
To test the hypothesis that fatty liver coexists with other metabolic abnormalities of the insulin resistance syndrome, and responds to their amelioration, we prospectively studied 48 consecutive patients with chronically elevated liver enzymes and clinical, ultrasound and histological findings consistent with fatty infiltration of the liver. Most of the patients were overweight or obese (64%) with increased waist circumference which closely relates to visceral fat. Only 10% of the patients had normal glucose tolerance: 44% had diabetes mellitus, 29% impaired glucose tolerance, and 17% were hyperinsulinaemic. The most common dyslipidaemia found was hypertriglyceridaemia and/or low HDL-C (86%). Dietary intervention and follow-up (median 24 months), supplemented by oral hypoglycaemic or lipid-lowering drugs as needed, resulted not only in weight loss (mean 3.7 kg), decreased fasting blood glucose (p < 0.005) and improvement in serum lipid profile (p < 0.02 for both triglycerides or HDL-C) but also in an improvement of serum liver enzymes in 96%, which became normal in more than half of the patients. Thus, fatty liver was strongly associated with many features of the insulin resistance syndrome, and follow-up revealed a high potential for reversibility and a benign course.
Similar articles
- Insulin resistance and metabolic syndrome in patients with NAFLD but without diabetes: effect of a 6 month regime intervention.
Cankurtaran M, Tayfur O, Yavuz BB, Geyik S, Akhan O, Arslan S. Cankurtaran M, et al. Acta Gastroenterol Belg. 2007 Jul-Sep;70(3):253-9. Acta Gastroenterol Belg. 2007. PMID: 18074733 - Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.
Mager DR, Yap J, Rodriguez-Dimitrescu C, Mazurak V, Ball G, Gilmour S. Mager DR, et al. Nutr Clin Pract. 2013 Feb;28(1):101-11. doi: 10.1177/0884533612454884. Epub 2012 Oct 5. Nutr Clin Pract. 2013. PMID: 23042833 - Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease?
Sargin M, Uygur-Bayramiçli O, Sargin H, Orbay E, Yayla A. Sargin M, et al. J Clin Gastroenterol. 2003 Nov-Dec;37(5):399-402. doi: 10.1097/00004836-200311000-00010. J Clin Gastroenterol. 2003. PMID: 14564188 - Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial.
Rusu E, Jinga M, Enache G, Rusu F, Dragomir AD, Ancuta I, Draguţ R, Parpala C, Nan R, Sima I, Ateia S, Stoica V, Cheţa DM, Radulian G. Rusu E, et al. Nutr J. 2013 Aug 14;12:119. doi: 10.1186/1475-2891-12-119. Nutr J. 2013. PMID: 23941362 Free PMC article. Clinical Trial. - Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test.
Guzzaloni G, Grugni G, Minocci A, Moro D, Morabito F. Guzzaloni G, et al. Int J Obes Relat Metab Disord. 2000 Jun;24(6):772-6. doi: 10.1038/sj.ijo.0801224. Int J Obes Relat Metab Disord. 2000. PMID: 10878685
Cited by
- Normal serum aminotransferase levels and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys.
Kim HC, Choi KS, Jang YH, Shin HW, Kim DJ. Kim HC, et al. Yonsei Med J. 2006 Aug 31;47(4):542-50. doi: 10.3349/ymj.2006.47.4.542. Yonsei Med J. 2006. PMID: 16941745 Free PMC article. - Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment.
Smith BW, Adams LA. Smith BW, et al. Nat Rev Endocrinol. 2011 May 10;7(8):456-65. doi: 10.1038/nrendo.2011.72. Nat Rev Endocrinol. 2011. PMID: 21556019 Review. - Noninvasive fatty liver markers predict liver disease mortality in the U.S. population.
Unalp-Arida A, Ruhl CE. Unalp-Arida A, et al. Hepatology. 2016 Apr;63(4):1170-83. doi: 10.1002/hep.28390. Epub 2016 Jan 22. Hepatology. 2016. PMID: 26663021 Free PMC article. - Comorbidities and Metabolic Derangement of NAFLD.
Bang KB, Cho YK. Bang KB, et al. J Lifestyle Med. 2015 Mar;5(1):7-13. doi: 10.15280/jlm.2015.5.1.7. Epub 2015 Mar 30. J Lifestyle Med. 2015. PMID: 26528424 Free PMC article. Review. - Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease.
Jarmakiewicz-Czaja S, Sokal A, Pardak P, Filip R. Jarmakiewicz-Czaja S, et al. Can J Gastroenterol Hepatol. 2022 May 11;2022:4344905. doi: 10.1155/2022/4344905. eCollection 2022. Can J Gastroenterol Hepatol. 2022. PMID: 35600209 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources